Michael Sumner | Chief Medical Officer
Inovio Pharmaceuticals

Michael Sumner, Chief Medical Officer, Inovio Pharmaceuticals

Dr. Sumner leads INOVIO’s clinical-stage pipeline of DNA medicines, global clinical development, clinical operations and biostatistics efforts, as well as regulatory affairs, pharmacovigilance and medical affairs. Dr. Sumner previously served as CMO of Orexo AB since 2013. He previously held numerous European- and US-based leadership roles at Novartis Pharmaceuticals, Aventis Behring, Novo Nordisk and Shire Pharmaceuticals. Dr. Sumner brings over 25 years of extensive pharmaceutical, medical and clinical experience driving numerous late-stage product approvals and supporting successful commercial products on a global basis across multiple therapeutic areas.

Dr. Sumner received his medical degree from the University of London, is a member of the Royal College of Physicians, and holds a Master of Business Administration from Henley Management College, UK.


Day 2 - Wednesday 3rd April @ 14:40

Advancing DNA Medicines: Clinical Learnings from Candidates Targeting Ebola and Recurrent Respiratory Papillomatosis - Title TBC

last published: 30/Nov/23 11:25 GMT

back to speakers